A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment

Response rate and toxicity of second-line therapy with docetaxel (75 mg m(−2)) or docetaxel, irinotecan, and lenogastrim (60 mg m(−2), 200 mg m(−2), and 150 μg m(−2) day(−1), respectively) were compared in 108 patients with stage IIIb–IV non-small-cell lung cancer. Addition of irinotecan to docetaxe...

Descripción completa

Detalles Bibliográficos
Autores principales: Wachters, F M, Groen, H J M, Biesma, B, Schramel, F M N H, Postmus, P E, Stigt, J A, Smit, E F
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361740/
https://www.ncbi.nlm.nih.gov/pubmed/15597104
http://dx.doi.org/10.1038/sj.bjc.6602268

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361740/
https://www.ncbi.nlm.nih.gov/pubmed/15597104
http://dx.doi.org/10.1038/sj.bjc.6602268

Ejemplares similares